Skip to Content
Morningstar

Insmed Inc INSM

Morningstar Rating
Unlock
Stock XNAS Rating as of
$24.92 −0.89 (3.45%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
INSM is trading within a range we consider fairly valued.
Price
$25.19
Fair Value
$44.83
Uncertainty
Very High
1-Star Price
$18.47
5-Star Price
$14.77
Economic Moat
Xtmc
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INSM is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$25.81
Day Range
$24.81–25.44
52-Week Range
$18.09–32.00
Bid/Ask
$11.27 / $26.40
Market Cap
$3.70 Bil
Volume/Avg
1.2 Mil / 1.8 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
11.11
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
912
Website
https://www.insmed.com

Comparables

Valuation

View More
Metric
INSM
AVTE
MIRM
Price/Earnings (Normalized)
 ———
Price/Book Value
 —5.474.60
Price/Sales
 11.11—5.37
Price/Cash Flow
 ———
Price/Earnings
INSM
AVTE
MIRM

Financial Strength

Metric
INSM
AVTE
MIRM
Quick Ratio
 3.646.944.07
Current Ratio
 4.127.044.45
Interest Coverage
 −8.82—−10.66
Quick Ratio
INSM
AVTE
MIRM

Profitability

Metric
INSM
AVTE
MIRM
Return on Assets (Normalized)
 −41.25%−48.35%−19.13%
Return on Equity (Normalized)
 —−53.58%−52.80%
Return on Invested Capital (Normalized)
 −51.82%−56.98%−25.39%
Return on Assets
INSM
AVTE
MIRM
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRBndtdcswNhw$554.7 Bil
VRTX
Vertex Pharmaceuticals IncZwdpygqxqHjmqsw$103.6 Bil
REGN
Regeneron Pharmaceuticals IncQycnmsjPqsgm$97.8 Bil
MRNA
Moderna IncQwbxqtqbZrc$38.8 Bil
ARGX
argenx SE ADRRvpjbwzpvDhh$22.0 Bil
BNTX
BioNTech SE ADRJwykpypKhb$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncDxdnqfwpQdnhpk$18.2 Bil
BMRN
Biomarin Pharmaceutical IncHvbrrkkZzlnvc$17.3 Bil
RPRX
Royalty Pharma PLC Class ADtyhcpzjvDldbpb$12.5 Bil
INCY
Incyte CorpQznkdyqnnNmvznj$11.5 Bil

Sponsor Center